Moreover, expression of matrix metalloprotease 2 (MMP2) and MMP9, which we have previously reported to be controlled by fascin in breast cancer cells (4), has been described as downstream targets of the β-catenin signaling pathway (16). This evidence concerns the gene FSCN1 and breast carcinoma.